Genetics and epigenetics of human retinoblastoma

Annual Review of Pathology: Mechanisms of Disease

Volumn 10, Issue , 2015, Pages 547-562

  Benavente, Claudia A ^a   Dyer, Michael A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

epigenetics; genetics; RB1; retinoblastoma

Indexed keywords

KIF14 PROTEIN; MICRORNA; PROTEIN; PROTEIN MDMX; UNCLASSIFIED DRUG; UVOMORULIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CHROMOSOMAL INSTABILITY; CHROMOSOMAL PARAMETERS; CHROMOSOME 16; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOTHRIPSIS; DNA METHYLATION; EPIGENETICS; GENE SEQUENCE; GENETIC ANALYSIS; GENETICS; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC EPIGENESIS; MUTATION; RETINA TUMOR; TUMOR SUPPRESSOR GENE;

EPIGENESIS, GENETIC; EPIGENOMICS; GENES, RETINOBLASTOMA; HUMANS; MUTATION; RETINAL NEOPLASMS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 84921930606     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012414-040259     Document Type: Article

References (100)

1. Knudson Jr. AG. 1971. Mutation and cancer: statistical study of retinoblastoma. PNAS 68:820-23
2. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, et al. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-46
3. Dunn JM, Phillips RA, Becker AJ, Gallie BL. 1988. Identification of germline and somatic mutations affecting the retinoblastoma gene. Science 241:1797-800
4. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
5. Manning AL, Longworth MS, Dyson NJ. 2010. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 24:1364-76
6. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, et al. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797-802
7. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, et al. 2008. Loss of RB1 induces nonproliferative retinoma: Increasing genomic instability correlates with progression to retinoblastoma. Hum. Mol. Genet. 17:1363-72
8. Amato A, Lentini L, Schillaci T, Iovino F, Di Leonardo A. 2009. RNAi mediated acute depletion of retinoblastoma protein (pRb) promotes aneuploidy in human primary cells via micronuclei formation. BMC Cell Biol. 10:79
9. Iovino F, Lentini L, Amato A, Di Leonardo A. 2006. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol. Cancer 5:38
10. Negrini S, Gorgoulis VG, Halazonetis TD. 2010. Genomic instability-An evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11:220-28
11. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, et al. 2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481:329-34
12. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, et al. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 43:294-301
13. Yan Y, Dunkel IJ, Guan X, Abramson DH, Jhanwar SC, O'Reilly RJ. 2000. Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice. Eur. J. Cancer 36:221-28
14. Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, et al. 2013. Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget 4:844-59
15. Squire J, Gallie BL, Phillips RA. 1985. A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Hum. Genet. 70:291-301
16. Squire J, Phillips RA, Boyce S, Godbout R, Rogers B, Gallie BL. 1984. Isochromosome 6p, a unique chromosomal abnormality in retinoblastoma: verification by standard staining techniques, new densitometric methods, and somatic cell hybridization. Hum. Genet. 66:46-53
17. Potluri VR, Helson L, Ellsworth RM, Reid T, Gilbert F. 1986. Chromosomal abnormalities in human retinoblastoma. A review. Cancer 58:663-71
18. Balaban-Malenbaum G, Gilbert F, Nichols WW, Hill R, Shields J, Meadows AT. 1981. A deleted chromosome no. 13 in human retinoblastoma cells: relevance to tumorigenesis. Cancer Genet. Cytogenet. 3:243-50
19. Chaum E, Ellsworth RM, Abramson DH, Haik BG, Kitchin FD, Chaganti RS. 1984. Cytogenetic analysis of retinoblastoma: evidence for multifocal origin and in vivo gene amplification. Cytogenet. Cell Genet. 38:82-91
20. Gilbert F, Balaban G, Breg WR, Gallie B, Reid T, Nichols W. 1981. Homogeneously staining region in a retinoblastoma cell line: relevance to tumor initiation and progression. J. Natl. Cancer Inst. 67:301-6
21. Cowell JK, Hogg A. 1992. Genetics and cytogenetics of retinoblastoma. Cancer Genet. Cytogenet. 64:1-11
22. Hogg A, Onadim Z, Baird PN, Cowell JK. 1992. Detection of heterozygous mutations in the RB1 gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. Oncogene 7:1445-51
23. Oliveros O, Yunis E. 1995. Chromosome evolution in retinoblastoma. Cancer Genet. Cytogenet. 82:155-60
24. Amare Kadam PS, Ghule P, Jose J, Bamne M, Kurkure P, et al. 2004. Constitutional genomic instability, chromosome aberrations in tumor cells and retinoblastoma. Cancer Genet. Cytogenet. 150:33-43
25. Corson TW, Gallie BL. 2007. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46:617-34
26. Grasemann C, Gratias S, Stephan H, Schuler A, Schramm A, et al. 2005. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 24:6441-49
27. Orlic M, Spencer CE, Wang L, Gallie BL. 2006. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 45:72-82
28. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, et al. 2004. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23:1627-30
29. Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, et al. 2006. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 25:6538-43
30. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, et al. 2004. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23:5871-79
31. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, et al. 2006. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 54:155-62
32. Hu H-G, Scholten I, Gruss C, Knippers R. 2007. The distribution of the DEK protein in mammalian chromatin. Biochem. Biophys. Res. Commun. 358:1008-14
33. Von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, et al. 1992. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol. 12:1687-97
34. Lin L, Piao J, GaoW, Piao Y, Jin G, et al. 2013. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 13:366
35. Lillington DM, Kingston JE, Coen PG, Price E, Hungerford J, et al. 2003. Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome. Genes Chromosomes Cancer 36:121-28
36. Herzog S, Lohmann DR, Buiting K, Sch uler A, Horsthemke B, et al. 2001. Marked differences in unilateral isolated retinoblastomas from young and older children studied by comparative genomic hybridization. Hum. Genet. 108:98-104
37. Nakagawa T, Tanaka Y, Matsuoka E, Kondo S, Okada Y, et al. 1997. Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. PNAS 94:9654-59
38. Wang Q, Wang L, Li D, Deng J, Zhao Z, et al. 2013. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol. 37:79-84
39. Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. 2012. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int. J. Cancer 130:1844-54
40. Corson TW, Gallie BL. 2006. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int. J. Cancer 119:1088-94
41. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. 2007. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin. Cancer Res. 13:3229-34
42. Madhavan J, Coral K, Mallikarjuna K, Corson TW, Amit N, et al. 2007. High expression of KIF14 in retinoblastoma: association with older age at diagnosis. Investig. Ophthalmol. Vis. Sci. 48:4901-6
43. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66
44. Roylance R, Gorman P, Papior T, Wan Y-L, Ives M, et al. 2006. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 25:6544-53
45. Laurie N, Mohan A, McEvoy J, Reed D, Zhang J, et al. 2009. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. Mol. Cell. Biol. 29:6268-82
46. Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, et al. 1996. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett. 106:75-82
47. Horn HF, Vousden KH. 2007. Coping with stress: multiple ways to activate p53. Oncogene 26:1306-16
48. Marine J-C, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. 2006. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13:927-34
49. Marine J-C, Jochemsen AG. 2004. Mdmx and Mdm2: brothers in arms?. Cell Cycle 3:900-4
50. Castera L, Sabbagh A, Dehainault C, Michaux D, Mansuet-Lupo A, et al. 2010. MDM2 as a modifier gene in retinoblastoma. J. Natl. Cancer Inst. 102:1805-8
51. de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, Ferman SE, Lucena E, et al. 2012. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr. Blood Cancer 59:39-43
52. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, et al. 2011. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20:260-75
53. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, et al. 2012. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLOS ONE 7:e42739
54. Chi P, Allis CD, Wang GG. 2010. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10:457-69
55. Lu J, Ruhf M-L, Perrimon N, Leder P. 2007.A genome-wideRNAinterference screen identifies putative chromatin regulators essential for E2F repression. PNAS 104:9381-86
56. Benetti R, Gonzalo S, Jaco I, Munoz P, Gonzalez S, et al. 2008. Amammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol. 15:998
57. Wen H, Andrejka L, Ashton J, Karess R, Lipsick JS. 2008. Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev. 22:601-14
58. Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, et al. 2009. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol. Biol. Cell 20:3192-99
59. Gonzalo S, Blasco MA. 2005. Role of Rb family in the epigenetic definition of chromatin. Cell Cycle 4:752-55
60. Chen K, Rajewsky N. 2007. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet. 8:93-103
61. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-33
62. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, et al. 2009. Identification ofmiRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Child's Nerv. Syst. 25:13-20
63. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, et al. 2011. miR-17-92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 25:1734-45
64. Li BQ, Zhang J, Huang T, Zhang L, Cai YD. 2012. Identification of retinoblastoma related genes with shortest path in a protein-protein interaction network. Biochimie 94:1910-17
65. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. 2009. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Investig. Ophthalmol. Vis. Sci. 50:4542-51
66. Jo DH, Kim JH, Park WY, Kim KW, Yu YS. 2011. Differential profiles ofmicroRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. J. Pediatr. Hematol. Oncol. 33:529-33
67. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-47
68. Lee YS, Dutta A. 2007. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21:1025-30
69. Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315:1576-79
70. Sampson VB, Rong NH, Han J, Yang Q, Aris V, et al. 2007. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67:9762-70
71. Mu G, Liu H, Zhou F, Xu X, Jiang H, et al. 2010. Correlation of overexpression ofHMGA1andHMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum. Pathol. 41:493-502
72. Huang JC, Babak T, Corson TW, Chua G, Khan S, et al. 2007. Using expression profiling data to identify human microRNA targets. Nat. Methods 4:1045-49
73. Martin J, Bryar P, Mets M, Weinstein J, Jones A, et al. 2013. Differentially expressed miRNAs in retinoblastoma. Gene 512:294-99
74. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26:745-52
75. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-34
76. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26:731-43
77. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-Arrest. Cell Cycle 6:1586-93
78. Sage J, Ventura A. 2011. miR than meets the eye. Genes Dev. 25:1663-67
79. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, et al. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17-92 family of miRNA clusters. Cell 132:875-86
80. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. 2005. A microRNA polycistron as a potential human oncogene. Nature 435:828-33
81. Olive V, Jiang I, He L. 2010. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 42:1348-54
82. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, et al. 2007. An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 282:2135-43
83. Woods K, Thomson JM, Hammond SM. 2007. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem. 282:2130-34
84. Nittner D, Lambertz I, Clermont F, Mestdagh P, K ohler C, et al. 2012. Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat. Cell Biol. 14:958-65
85. Reis AH, Vargas FR, Lemos B. 2012. More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front. Genet. 3:284
86. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. 1989. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83:155-58
87. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. 1991. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 48:880-88
88. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. 1993. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8:1063-67
89. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, et al. 1997. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet. Cytogenet. 98:43-49
90. Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, et al. 2003. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am. J. Hum. Genet. 72:253-69
91. Livide G, Epistolato MC, Amenduni M, Disciglio V, Marozza A, et al. 2012. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol. Oncol. Res. 18:703-12
92. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, et al. 2002. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21:4345-49
93. Choy KW, Lee TC, Cheung KF, Fan DS, Lo KW, et al. 2005. Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia 7:200-6
94. Indovina P, Acquaviva A, De Falco G, Rizzo V, Onnis A, et al. 2010. Downregulation and aberrant promoter methylation of p16INK4A: a possible novel heritable susceptibility marker to retinoblastoma. J. Cell. Physiol. 223:143-50
95. Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, et al. 2013. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 14:327-34
96. Sears R, Ohtani K, Nevins JR. 1997. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol. Cell. Biol. 17:5227-35
97. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. 2000. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol. Cell. Biol. 20:3633-39
98. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, et al. 2001. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol. Cell 8:105-13
99. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40
100. McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, et al. 2014. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 5(2):438-50